T
he Fontan procedure has been performed since 1971 1 to treat various serious congenital heart defects, including pulmonary atresia with intact ventricular septum, tricuspid atresia, hypoplastic left-heart syndrome, and other complex congenital heart diseases (CHDs) requiring a single-ventricle repair pathway. Many survivors of the procedure are now adults, are starting to experience many problems as a result of Fontan physiology (known as "Fontan failure"), and are seeking care in settings other than pediatric cardiology units. They may now be seen in adult cardiology, cardiac surgery, transplant, and emergency departments; obstetrical services; and other settings as they encounter noncardiac health problems. Understanding the unique Fontan physiology and how it affects assessment and treatment of these patients has become increasingly important for nurses working in areas other than pediatric cardiac settings. For hospitals that have continued to observe adults in pediatric cardiac settings, pediatric nurses increasingly will see patients with Fontan failure; therefore, understanding the long-term outcomes of the Fontan procedure is increasingly important. 
Fontan Procedure

A B S T R A C T
The Fontan procedure is used to treat various serious congenital heart defects. Although many people who have had the procedure live productively into adulthood, as they age, they face several health issues due to the physiology of the Fontan circulation. This article reviews the 4 types of Fontan procedures and the changes caused by the surgery, including single-ventricle physiology, nonpulsatile pulmonary perfusion, systemic venous hypertension, and intracardiac scarring, as well as their sequelae. Key nursing assessment items and possible treatment strategies are reviewed. Additional topics, including pregnancy in patients who have
Fenestrations come at the expense of lower oxygen saturations (in the mid-70s to low 90s, depending on how much shunting is occurring) and pose a risk for paradoxical embolization if any air or thrombus enters the venous system and crosses over into the arterial system through the fenestration. Paradoxical embolization may result in stroke, limb ischemia, and emboli to abdominal organs. Many institutions use hydrophobic air filters (with pore sizes less than 0.40 micron) on intravenous catheters to prevent air embolization. However, these devices cannot be used when infusing blood products, lipid infusions, or other drugs with a large molecular size, such as mannitol, as these products are larger than the pore size in the filters. With fenestrations and lower saturations, compensatory erythropoiesis occurs, resulting in higher than normal hematocrit levels. Clinicians need to keep in mind that the lower the saturations, the higher the hematocrit level must be kept to permit optimal oxygenation (generally at least 45%). Fenestrations may close spontaneously over time if there is minimal flow through them, they may be closed in the cardiac catheterization laboratory with occlusion devices, or they may be closed by tightening sutures placed around the fenestration at the time of surgery.
Fontan Physiology
Unique physiological changes caused by Fontan circulation (with the exception of the AV Fontan) include (1) a single-ventricle circulation (sometimes with a systemic right ventricle), (2) passive (nonpulsatile) venous flow to the lungs instead of the normal pulsatile lung perfusion, (3) systemic venous hypertension, and (4) scarring in the heart (except for the EC Fontan) .
Sequelae of Fontan Physiology
The sequelae of the 4 major physiological changes after the Fontan procedure can result in Fontan failure with cardiac and noncardiac manifestations. The sequelae of each of these changes are reviewed later. Key points in the nursing assessment of patients who have undergone the Fontan procedure and suggestions for treatment are summarized in Table 1 .
Single-Ventricle Circulation
The single ventricle has increased work to perform, as it must pump blood to the body and also generate enough force to drive blood the late 1970s by Bjork et al 3 for individuals with tricuspid atresia and a right ventricle of least moderate size, and it is the only Fontan variant that maintains biventricular circulation. Therefore, individuals with an AV Fontan may not necessarily experience Fontan problems if the morphological right ventricle is of sufficient size and contributes significantly to cardiac output and pulsatile pulmonary perfusion. The next iteration of the procedure, the lateral tunnel (LT) Fontan, was developed by de Leval and colleagues 4 in the late 1980s. The most recent Fontan procedure is the extracardiac (EC) Fontan developed in the 1990s by Marcelletti and colleagues. 5 The latter 2 Fontan procedures are sometimes referred to as total cavopulmonary connections, because the superior and inferior venae cavae are connected directly to the pulmonary circulation.
Some institutions are currently performing and evaluating hybrid Fontan procedures in the population with hypoplastic left-heart syndrome. The hybrid Fontan procedure involves construction of an EC Fontan in the cardiac catheterization laboratory using a covered stent to direct blood flow from the inferior vena cava to the superior vena cava (SVC), after a surgical setup to complete the Fontan occurs intraoperatively during the Glenn shunt procedure (SVC to pulmonary artery [PA] anastomosis) and aortic arch reconstruction. 6 Medium-and longterm outcomes of the hybrid approach are lacking and are not addressed in this article.
Survival free of death or heart transplantation after the Fontan procedure is about 75% at 10 years, 68% at 20 years, and 54% at 25 years. When survival free of death or transplantation is examined in perioperative survivors (to account for the higher risk of surgery in earlier Fontan eras), the long-term survival is not significantly different between Fontan types. 7 Clinicians must know whether the Fontan procedure contained a fenestration and whether the fenestration is still patent. Fenestrations are sometimes performed on the LT and EC variants of the Fontan procedure (between the conduit and the common atrium) for the purpose of allowing right-to-left shunting if venous pressures get too high in the early postoperative period. The rationale for performing a fenestration is that it may result in fewer prolonged pleural effusions and improve cardiac output as blood flow bypasses the restrictive factor in the circuit, which is pulmonary vascular resistance. Defi ciencies in protein C; factors II, V, VII, and X; plasminogen; and antithrombin III are common. Higher factor VIII levels may be present.
Patients with fenestrated Fontans or those with known thromboemboli or atrial arrhythmias should be therapeutically anticoagulated. All patients with Fontans who are not on anticoagulants should be on low-dose aspirin (75-100 mg daily).
Pleural effusions Assess for decreased air entry to the lung bases, hypoxemia, and dyspnea. Observe for pleural effusions on chest x-ray, dullness to percussion over the lower thorax.
High systemic venous pressure causes fl uid to move into the pleural space.
Restrict salt/fl uid intake. Treatment with diuretics may be required.
Pleurocentesis or chest tube insertion may be required if the pleural effusions are large or if the patient is dyspneic.
(continues) Heart Association (ACC/AHA) 2008 ACHD guidelines make a class IIa recommendation (benefit greater than risk but additional studies with focused objectives needed) that treating single-ventricle dysfunction with angiotensinconverting enzyme inhibitors and diuretics is reasonable, 14 but further study of medications treating heart failure in this patient population, particularly in adults, is needed.
In addition, little evidence is available for the use of cardiac resynchronization therapy 15 or implantable cardioverter-defibrillators (ICDs) in patients who have undergone the Fontan procedure. As a result of lack of access from the systemic venous system into the heart with all types of Fontans except the AV Fontan unless a fenestration is present, the leads for cardiac resynchronization therapy and ICDs need to be placed on the epicardium. Although epicardial leads can be placed with a subxiphoid approach or minithoracotomy approach, extensive adhesions may preclude such placement, necessitating sternotomy or thoracotomy versus the usual transvenous approach used in individuals with a biventricular circulation. For this reason, the leads are typically implanted at Fontan revision surgery and tunneled into the abdomen for potential generator implantation, if needed, at a later date. One detractor of inserting ICDs in patients with ACHD is the higher incidence of inappropriate shocks in younger patients with ACHD. 16 Referral for heart transplantation is undertaken for severe ventricular dysfunction, despite optimal medical therapy.
Passive Venous Flow to the Lungs
The lungs are not perfused by ventricular ejection, because no subpulmonary ventricle (other than in the AV Fontan) exists. The pressure difference between the right atrium and the left atrium drives flow through the pulmonary bed. 17 Pulmonary vascular resistance is increased because of the lack of pulsatility (pulsatility induces shear stress-mediated release of endothelium-derived nitric oxide, a pulmonary vasodilator) 18 and endothelial dysfunction 9 from elevated levels of endothelin-1 (a pulmonary vasoconstrictor) found in patients who have undergone the Fontan procedure. 19 If pulmonary vascular resistance increases above baseline values, for example, with hypoxemia or hypercapnia, pulmonary perfusion will decrease. Therefore, good oxygenation and avoidance of hypercapnia are useful in avoiding elevated pulmonary vascular across the pulmonary bed as (with the exception of the AV Fontan) no ventricle exists to pump blood through the pulmonary circulation. Cardiac output is determined by the pulmonary vascular resistance that the single ventricle must overcome to achieve cardiac output. 8 The single ventricle is sometimes a morphological right ventricle that is not structurally designed to pump at systemic pressures for years, particularly with the elevated pulmonary vascular resistance that is present in a Fontan circulation. In addition, endothelial dysfunction occurs after the Fontan procedure, likely because of abnormalities in the nitric oxide pathway 9 , and this dysfunction may cause increased systemic vascular resistance. The additional burden of the single ventricle having to overcome this increased systemic vascular resistance to eject blood into the aorta may interact with single-ventricle dysfunction to produce heart failure.
With a systemic right ventricle, the systemic AV valve is a tricuspid valve that is not structurally designed to function at systemic pressures for years, unlike a mitral valve. Systemic AV valve regurgitation may occur and further complicate heart failure. Moderate and severe AV valve regurgitation were present in 19% and less than 1%, respectively, of patients in the Contemporary Outcomes After the Fontan Study. 10 Systemic AV valve regurgitation can be treated by valve repair or replacement if it is moderate to severe and causing symptoms.
The use of the neurohormonal biomarker brain natriuretic peptide has been validated in adult patients who have congenital heart disease (ACHD) of varying classes of heart failure and systemic ventricular dysfunction, including patients with a single-ventricle. 11 The role of medications, other than diuretics, to treat heart failure in the failing single ventricle is less well documented than for biventricular physiology. The Pediatric Heart Network multicenter, randomized trial 12 failed to demonstrate any advantage in ventricular function or heart failure severity when enalapril was administered to infants with a single ventricle. A large multicenter, randomized, double-blind trial of carvedilol versus placebo failed to show any improvement in clinical heart failure outcomes in pediatric patients with heart failure, some of whom had CHD. Notable were poorer outcomes in patients with a systemic right ventricle versus a systemic left ventricle. In the AV Fontan, one would not want to leave an indwelling PA pressure catheter across the AV connection because of the risk of thrombus. Cardiac output calculated from an indwelling PA catheter of the thermodilution type would not provide correct calculations in a patient with Fontan circulation, as the assumptions underlying the calculation of cardiac output are based on normal intracardiac anatomy. The jugular venous pressure is frequently at the jaw or higher, and pressure transduced from a neck catheter often is greater than 15 mm Hg, reflecting mean PA pressure. Most bedside cardiac monitors do not have an option to label neck-catheter venous pressures as "Fontan pressure" or "mean PA" pressure; therefore, bedside caregivers must be knowledgeable about what this number means and communicate this information to all interdisciplinary team members, so that it is not misinterpreted and used inappropriately in treatment decisions. Treating a patient with a Fontan pressure of 15 mm Hg with diuretics may result in underfilling of the single ventricle and impair cardiac output. Individual assessment and recognition of the fact that the neck vein pressure reflects mean PA pressure must occur.
Early after the Fontan procedure, systemic venous hypertension can result in SVC syndrome. Later, catheters in the neck veins and clot or stenosis of the SVC can cause SVC syndrome. Several prothrombotic factors in patients with Fontan physiology (see later discussion) can increase the likelihood of SVC clot, as can smoking and the use of estrogencontaining medications, such as some oral contraceptives. 26 Superior vena cava syndrome can cause the head to be edematous and upper chest neck veins to be prominent. Elevation of the head of the bed to greater than 45 ° is used to decrease edema. Ultrasound surveillance for clots should be undertaken. Salt and fluid restrictions as well as diuretics may be indicated to decrease the edema if no clot is found.
Because of the systemic venous hypertension, venous channels closed off in embryological development may reopen when exposed to elevated pressures. New venous collaterals also can form, draining to an atrium, a pulmonary vein, the coronary sinus, or the inferior vena cava. 27 Similarly, arteriovenous malformations (AVMs), which are abnormal connections between small arteries and veins, may occur as a result of systemic venous hypertension as well resistance. Ventilating with minimal or no positive end-expiratory pressure also facilitates venous drainage into the heart and can augment cardiac output. Early extubation, if the patient is otherwise stable, also negates the negative effects of positive pressure ventilation in patients who have undergone the Fontan procedure.
Patients with Fontan physiology generally have decreased exercise capacity as pulmonary vascular resistance needs to decrease to increase cardiac output during exercise. The chronically elevated pulmonary vascular resistance in patients with Fontan physiology is a limiting factor in exercise. Mean PA pressure also is known to increase during exercise with age in normal individuals with biventricular physiology. 20 Therefore, patients with Fontan physiology increasingly may experience further reductions in exercise capacity as they age. Cardiopulmonary exercise testing is useful every few years to objectively and serially assess exercise tolerance.
Evidence from small trials of the effectiveness of pulmonary vasodilators such as nitric oxide 18 , 21 and sildenafil 22 , 23 has shown improved cardiac output and/or exercise capacity 22 and lower PA pressure in patients who have undergone the Fontan procedure. 24 Most of these trials involved short-term therapy only. A small pilot study with bosentan, a pulmonary vasodilator that targets endothelin, failed to show significant improvement in exercise capacity, oxygen saturation, or quality of life in patients with failing Fontan circulations. 25 Larger studies of longer use of various pulmonary vasodilators in the Fontan physiology are needed.
Systemic Venous Hypertension
In the Fontan procedure (except the AV Fontan), blood entering the SVC flows either directly into the PA (LT or EC Fontan) or into the right atrium, which is directly connected to the PA (AP Fontan). Therefore, jugular venous pressure does not reflect intracardiac preload but rather PA pressure. Similarly, pressure transduced from a jugular or subclavian catheter does not reflect intracardiac preload but rather mean PA pressure. As pulmonary perfusion is nonpulsatile (except in the AV Fontan), the jugular veins are nonpulsatile. Indwelling PA catheters of the thermodilution type cannot be used in patients with Fontan physiology in intensive care units because of lack of anatomic access to the pulmonary circulation from the venous circulation, except in the AV Fontan.
those with significant liver impairment should be referred to a hepatologist for ongoing management. Patient education about avoiding further liver injury with ethanol or other liver toxins should be provided. Individuals with significant liver dysfunction pose a higher risk for reoperation and for transplantation.
Individuals who had blood transfusions prior to 1992 when hepatitis screening of blood was instituted are also at risk for hepatitis B and C infections, which may add to hepatic injury. Therefore, all adults who have undergone the Fontan procedure who have not been screened for hepatitis B and C should undergo screening.
Deficiencies in protein C; factors II, V, VII, and X; plasminogen; and antithrombin III as well as higher factor VIII levels may result from poor hepatic function and cause a hypercoagulable state. 32 Low-dose aspirin (75-100 mg daily) is suggested, 33 , 34 or if at higher risk for thrombus, such as with atrial arrhythmias or known atrial clot, therapeutic anticoagulation is needed. 33 The ACC/AHA 2008 ACHD guidelines 14 recommend warfarin as a class I intervention for patients with a documented atrial shunt, atrial thrombus, atrial arrhythmias, or a thromboembolic event. A recent multicenter, randomized trial comparing warfarin and aspirin for thromboprophylaxis after the Fontan procedure in patients without atrial arrhythmias showed an overall thrombosis rate of 19% two years postoperation and no difference in thrombosis rates between the 2 treatments. 35 Newer anticoagulants such as dabigatran have not been studied in patients with Fontan physiology.
High systemic venous pressure can cause fluid to move into the pleural or pericardial space, resulting in pleural or pericardial effusions. These effusions can generally be treated medically and often do not require drainage.
Protein can leak into the intestine and other interstitial spaces and cause protein-losing enteropathy (PLE). 36 The pathophysiology of PLE is not completely understood but likely involves a combination of systemic venous hypertension, inflammation, low cardiac output, and increased mesenteric vascular resistance, leading to decreasing mesenteric perfusion. 37 Protein-losing enteropathy is manifest as ascites, peripheral edema, diarrhea, abdominal pain, pleural and pericardial effusions, hypoproteinemia, and frequent infections. 36 , 38 Chronic protein loss results in hypocalcemia with possible muscle tetany as exclusion of hepatic blood from the pulmonary circulation (in the AP Fontan) and higher levels of vascular endothelial growth factor in patients with Fontan physiology. 28 Venous collaterals and AVMs may divert blood from the lungs and hence may result in hypoxemia. Venous collaterals and AVMs may be treated with coil embolization in the cardiac catheterization laboratory if they cause hypoxemia. Surgical revision to include hepatic venous blood into the pulmonary circulation when collaterals and AVMs are not amenable to transcatheter management is a class I recommendation (benefit greater than risk and procedure or treatment should be performed/administered) in the ACC/AHA 2008 ACHD guidelines.
14 Systemic venous hypertension may cause chronic venous insufficiency, resulting in varicose veins and leg ulcers. 29 Multiple femoral cardiac catheterizations and previous deep vein thrombosis are also predictors of chronic venous insufficiency in patients with Fontan physiology. 29 Chronic venous insufficiency may require treatment with compression hosiery.
High systemic venous pressures are transmitted to the liver via the inferior vena cava and hepatic venous circulation. High systemic venous pressures can lead to portal hypertension, esophageal varices, ascites, and liver changes, such as sinusoidal dilatation, liver fibrosis, centrilobar necrosis, cirrhosis, and hepatocellular carcinoma. Upper gastrointestinal bleeding can occur with varices. Bryant et al 30 found arterialized liver nodules in patients with Fontan physiology, with higher mean right atrial pressures and higher systemic ventricular end-diastolic pressures versus those with lower pressures. The exact pathophysiology of the liver changes in the Fontan circulation is not completely understood, but reduced cardiac output and relative hypoxemia also may play a role. 31 Hepatic assessment is difficult, as liver enzymes, bilirubin, and international normalized ratio may be normal or only mildly elevated, because inflammation is not the primary pathophysiological mechanism as opposed to other liver pathologies such as hepatitis. The liver edge may feel irregular and firm. Jaundice is generally a late sign. Ultrasonography, elastography, and computed tomography/magnetic resonance imaging often are used for initial liver assessment. Liver biopsy and transhepatic gradients often are required to fully assess the liver. 30 All patients with Fontan circulation should be assessed for liver dysfunction, and was only from 5 to 12 years postoperation. Longer follow-up to determine which procedure is superior for arrhythmia prevention is needed. When the stasis of blood caused by atrial flutter and atrial fibrillation is added to the prothrombotic changes previously described, the potential for intracardiac clot and pulmonary emboli increases further. Atrial arrhythmias also decrease cardiac output as a result of the loss of atrial contraction contribution to cardiac output. Hence, the risk of heart failure increases further in those with atrial arrhythmias.
The most common atrial arrhythmia in patients who have undergone the Fontan procedure is IART, also known as incisional tachycardia, which is a reentrant atrial arrhythmia with a constant cycle length 47 that usually has an atrial rate of 150 to 250/min (slower than typical atrial flutter that usually has a rate of about 300/min). Often, it is conducted 1:1 or 1:2 to the ventricle. Intra-atrial reentrant tachycardia with 1:2 conduction to the ventricle can easily be mistaken as sinus tachycardia. Identification of IART can be facilitated with a Valsalva maneuver or, in patients with temporary pacemaker wires or permanent pacemaker leads, by the use of atrial electrograms. See Figure 2 for an illustration of IART. Intra-atrial reentrant tachycardia can precipitate heart failure and hemodynamic compromise within a short period of time in patients with singleventricle physiology, such as the Fontan, and should, therefore, be treated promptly. The ACC/AHA 2008 ACHD guidelines make a class I recommendation to be mindful of the high risk for symptomatic IART in adults who have undergone the Fontan procedure. 14 Anticoagulation will need to be started with recurrent or persistent IART. Patients with an AP Fontan are at high risk for thrombus formation due to their enlarged right atria with sluggish flow; IART only serves to increase this risk. Embolization from the right atrium will result in pulmonary embolus. One study found a silent pulmonary emboli prevalence of 17% in patients who had undergone the Fontan procedure (60% AP Fontans). 48 Intra-atrial reentrant tachycardia can be treated with antitachycardia pacing 49 and can be cardioverted if clinicians can determine that no clot is present in the atrium with a transesophageal echocardiogram. Cardioversion is best performed with defibrillator pads in the anterior-posterior position, especially in and immunodeficiency as a result of immunoglobin loss. Protein-losing enteropathy occurs in about 4.2% of patients who have undergone the Fontan procedure, with a median time from operation to PLE diagnosis of 10 years 39 ; PLE has a mortality rate of 50% (5-year survival rate of 49%-59%). 38 , 39 Protein-losing enteropathy is diagnosed by clinical symptoms, a low serum protein or albumin level, and a high fecal α -1 antitrypsin level. No highly effective treatments are available for PLE, but the general approach is to treat heart failure, administer steroids (including oral budesonide) 40 and heparin (for its binding effect on cytokines involved in inflammation known to disrupt tight junctions and contribute to protein leakage), 41 provide a high-protein and low-fat diet, and convert AP and AV Fontans to an EC Fontan. If these options fail or the patient is considered too high risk for Fontan conversion, heart transplantation is the only treatment.
Protein leaking into the airways can cause plastic bronchitis, 42 a condition in which proteinaceous plastic-like casts obstruct the airways. Bronchoscopy may be required for cast removal.
Intracardiac Scarring
All types of the Fontan procedure except the EC Fontan leave behind scar tissue in the heart as the incisions heal. Scar tissue along with atrial distension from venous hypertension can lead to atrial arrhythmias and sinus node dysfunction. 43 In particular, in patients with AP Fontans, a huge right atrium develops over time, which may explain the higher incidence of atrial arrhythmias seen in this type of Fontan connection. Moderate to severe AV valve regurgitation also may increase atrial stretch. The incidence of atrial arrhythmias increases up to 50% by 15 to 20 years postoperatively and is highest in those with an AP Fontan. 43 -45 The LT Fontan was designed to have less atrial scarring than the AP Fontan, and the EC Fontan was designed to have no atrial scarring, with the hope that the rate of late atrial arrhythmias would be lower. A recent review of late arrhythmias after the Fontan procedure 46 found that the incidence of supraventricular arrhythmias, such as intra-atrial reentrant tachycardia (IART), was 40% to 65% for the AP Fontan, and 13% to 60% for the LT Fontan at 15 years postoperation. Similar arrhythmias existed in 8% to 15% of patients with EC Fontans, but follow-up for this group venous atrium to perform ablation is limited in LT and EC Fontans unless a fenestration exists. Yap and colleagues 47 demonstrated an acute procedural ablation success of 53% in adult patients who had undergone a Fontan procedure, with freedom from IART recurrence after successful ablation of 89% at 6 months, 31% at 2 years, and 15% at 4 years. Older age at ablation was a risk factor for IART recurrence. Other options for IART treatment include antitachycardia pacing, but positioning epicardial pacing leads for good sensing may be difficult as a result of postoperative adhesions. 50 If undertaking a Fontan conversion for Fontan failure, surgeons can use a right-atrial maze procedure for IART. If atrial fibrillation is present, a biatrial maze procedure is performed. 51 Sinus node dysfunction is common after the Fontan operation. Loss of sinus rhythm occurs as a result of atriotomies, injury to the sinus node or its arterial blood supply during surgery, venous hypertension with chronic atrial stretch, or left isomerism (2 morphological left atria with no true sinus node rather than a morphological right and left atrium). In the Contemporary Outcomes After Fontan Procedure multicenter study, 67% of patients were in sinus rhythm after Fontan, 9% had an atrial escape rhythm, 8% had a junctional escape rhythm, and 8% were paced. 10 β -blockers and other negative chronotropic drugs such as nondihydropyridine calcium channel blockers should be used cautiously (low starting dose and slow upward titration) in patients with Fontan physiology with arrhythmias because of the propensity for sinus node disease and should be avoided in documented sinus node disease. Treatment of sinus node dysfunction is insertion of a permanent pacemaker. Epicardial pacemaker wires are needed because of lack of access to the ventricle from the SVC as a result of the Fontan procedure, except in the AV Fontan.
Ventricular tachycardia from the right ventricular outflow tract may develop in patients with an AV Fontan as a result of scarring from the right ventriculotomy. 46 If frequent or symptomatic ventricular tachycardia occurs, amiodarone or other antiarrhythmics may be administered. Addressing underlying ventricular dysfunction also may decrease ventricular tachycardia. Fontan conversion may be considered for AV Fontans with ventricular tachycardia. 52 patients with an AP Fontan, to convert the massively dilated right atrium. Higher energy (often about 200 J) may be needed to cardiovert the IART. 50 Radiofrequency ablation has shown mixed results for IART, with recurrence rates of 32% to 100% 50 because of the difficulty of getting transmural lesions in the thick right atrium. Venous access to the systemic 
Other Issues
Pregnancy and Contraception
Low cardiac output may contribute to the increased incidence of spontaneous abortion and preterm labor as well as maternal heart failure noted in patients with Fontan physiology. 53 , 54 The ACC/AHA 2008 ACHD guidelines have a class I recommendation that all women with a Fontan connection should have a comprehensive evaluation by a physician with ACHD expertise before planning a pregnancy. In addition, the guidelines make a class III recommendation (risk greater than benefit and procedure or treatment should not be performed/administered because it is not helpful and may be harmful) that pregnancy should not be planned in patients with Fontan circulation without consultation and evaluation at a comprehensive ACHD center with experience and expertise in maternal and prenatal management of complex CHD.
14 For women who plan to become pregnant, genetic counseling may be indicated, if not already performed, to assess the likelihood of CHD in the offspring. During pregnancy, the fetus should be screened for CHD. For patients being treated with warfarin, consideration must be given to the risk of first-trimester fetal embryopathy as well as bleeding at delivery and what the best course of anticoagulation is during the pregnancy. Patients being treated with angiotensinconverting enzyme inhibitors need to have these withdrawn during pregnancy because of reports of fetal injury and death in the second and third trimesters. As a result of the increased risk of thromboembolism in patients with Fontan circulation, women seeking contraception should avoid using estrogen-containing contraceptives. Progesterone-only injections and implants are reasonable options. If a woman with a Fontan circulation elects surgical sterilization, laproscopic sterilization can cause hazardous decreases in cardiac output as a result of carbon dioxide insufflation and head down tilting as well as positive pressure ventilation needed for the procedure. Hysteroscopically inserted fallopian stents placed under local analgesic and sedative agents may be an alternative. Sterilization procedures should be planned with the congenital cardiologist collaborating with a gynecologist familiar with Fontan circulation. 52 
Prevention of Infective Endocarditis
The 2008 AHA/ACC ACHD guidelines 14 suggest the use of antibiotic drugs for infective endocarditis prophylaxis for patients with Fontan physiology with cyanosis (this would include fenestrations), with a previous history of infective endocarditis, with valve replacement, during the 6-month period after heart surgery (such as Fontan conversion), following an interventional procedure in which a prosthetic device was placed, or with residual patch leaks. Tattoos and piercings may increase the risk for bacteremia and should be discouraged.
Health-Related Quality of Life
Survivors of the Fontan procedure have a lower health-related quality of life (HRQOL) than age-matched controls 10 , 55 and their siblings. 56 Ongoing studies of HRQOL, as patients who have undergone the Fontan procedure age and develop Fontan failure, will be important to guide interventions. Patients with Fontan physiology also report higher levels of depression than healthy controls. 55 Surveillance and treatment of clinical depression are vital as HRQOL declines. Self-report or clinical depression scales can be used. Referral to psychiatry may be needed for treatment. If arrhythmias are found, an antidepressant needs to be selected to avoid QT-interval prolongation and proarrhythmia effects.
Fontan Failure
The collective negative effects of the singleventricle physiology, systemic venous hypertension, and intracardiac scarring lead to a pathophysiological state often referred to as "Fontan failure." Although some authors consider only the cardiac manifestations of the Fontan physiology when diagnosing Fontan failure, researchers increasingly recognize that multisystem assessment needs to guide the diagnosis of Fontan failure. The clinical indicators of Fontan failure are listed in Table 2 . No guideline is available as to how many indicators need to be present to diagnose the condition. Although many studies have attempted to address the predictors of Fontan failure to gain knowledge about when and how to intervene, the studies suffer from imprecise and variable definitions of Fontan failure, and few studies examine long-term outcomes after surgery. 57 -61 Fontan failure may result in decreased quality of life. Treatment is focused on the underlying cause of the Fontan failure where specific pathophysiology can be targeted, Fontan conversion to an LT or EC Fontan, or heart transplantation. venous cannula when venous flow goes directly to the lungs rather than first through the heart as in the LT and EC Fontans. In this situation, blood removed from the vena cava must be oxygenated extracorporeally, or an inflow cannula must be inserted into the PA confluence behind the conduit (which may be technically difficult). The cannulas may need length or size adjustment to accommodate the anatomy or afterload. Case reports are available on the use of the Berlin heart ventricular assist device as a bridge to recovery or transplantation in patients with Fontan circulation, albeit mostly pediatric patients. 66 -69 Generally, single inflow and outflow cannula are used instead of dual inflow and outflow cannula unless the Fontan circulation is taken down prior to implantation. First-line treatment of acute ventricular decompensation not responding to pharmacological treatment has been extracorporeal membrane oxygenation. However, this modality is suited only to shortterm support, primarily as a bridge to urgent transplantation. Total artificial hearts may offer more options for patients with Fontan circulation, but experience with these devices is limited.
Heart Transplantation
The ACC/AHA 2008 ACHD guidelines recommend heart transplantation for severe single-ventricle dysfunction or PLE (class IIb, benefit greater than risk, procedure/treatment may be considered but additional studies with broad objectives needed/additional registry data would be helpful).
14 Heart transplantation is difficult in the Fontan population as a result of allosensitization from homografts that may have been placed during surgery prior to the Fontan and from blood transfusions required perioperatively. 70 Technical difficulties, such as the need for PA and SVC reconstruction at the time of transplantation, make the surgery long 71 and often require donor hearts with extended lengths of arterial and venous connections. All of these factors result in longer wait times for a heart versus other non-ACHD adult patient waiting times. 72 Increased bleeding from adhesions and liver dysfunction are common. 73 Early outcomes for heart transplantation are poorer among patients with Fontan circulation than among patients without CHD in most 71 , 73 -76 but not all studies. 77 Heart-lung transplantation may be needed as a result of high pulmonary vascular resistance.
Fontan Conversion
The ACC/AHA 2008 ACHD guidelines recommend conversion of an AP Fontan to an EC Fontan if the patient has recurrent atrial fibrillation or flutter without hemodynamically significant anatomic abnormalities (class IIa recommendation). A concomitant maze procedure is recommended at the time of Fontan conversion.
14 Another indication for Fontan conversion would be pulmonary venous obstruction by the enlarged right atrium in the AP Fontan. 62 Fontan conversion surgery to an EC Fontan with arrhythmia surgery has a reported operative survival rate of 86.7% to 99.2%. 50 , 63 -65 Ventricular Assist Devices, Extracorporeal Membrane Oxygenation, and Total Artificial Heart
Although commonly used in end-stage heart failure for acquired heart disease and other types of biventricular failure of congenital origin, ventricular assist devices are rarely used for single-ventricle physiology because of the technical problems of insertion of the devices. Problems include placement of the 
Future Prospects
Laboratory studies are currently underway to develop a low-pressure, implantable pump for the Fontan circulation that would provide pulsatility to the pulmonary circulation and reduce systemic venous hypertension. 78 -81 This type of pump would effectively convert the univentricular Fontan circulation into a biventricular circulation. This type of intervention might avoid some of the current problems with Fontan physiology. Initially, such pumps likely will be applied in situations of Fontan failure as a bridge to transplant or as a bridge to recovery, with the eventual goal of creating a biventricular Fontan circulation for all individuals undergoing this surgery.
79
Summary
The Fontan procedure has enabled many infants with severe CHD to survive to adulthood and lead productive lives. However, the single-ventricle physiology, nonpulsatile pulmonary perfusion, systemic venous hypertension, and intracardiac scarring created by the Fontan procedure lead to ongoing health issues that cause Fontan failure and increase morbidity and mortality rates over time. Nurses and other healthcare professionals will play a key role in knowledgeably assessing and treating these patients as adults to maximize HRQOL.
